Condition: MDS (Myelodysplastic Syndrome) · Sponsor: Yale University
This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in non-mutated SF3B1 , lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level \< 500 IU/L.
This description comes directly from the study's public registry record.
Stephanie Ladd · 9548950576 · stephanie.ladd@yale.edu
Always discuss trial participation with your own doctor first.
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago, Illinois, United States | Not Yet Recruiting |
| Harold C. Simmons Comprehensive Cancer Center of UT Southwestern | Dallas, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07096297